根据提供的文献内容，我将提取并整理相关信息到JSON格式中。以下是提取的信息：

```json
{
    "Variants Include": [
        {
            "Gene": "SNCA",
            "variants": [
                {
                    "HGVS": "NM_000345.4:c.137G>A",
                    "cDNA Change": {
                        "transcript": "NM_000345.4",
                        "ref": "G",
                        "alt": "A",
                        "position": "137"
                    },
                    "Protein Change": {
                        "ref": "E",
                        "alt": "K",
                        "position": "46"
                    },
                    "Description in input context": "E46K"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease",
        "MONDO": "MONDO:0005072"
    },
    "Experiment Method": [
        {
            "Assay Method": "Planar lipid bilayer technique",
            "Material used": {
                "Material Source": "Synthetic lipid membranes",
                "Material Name": "DOPC, DOPC-GM3, DOPC-GM1, DOPC-GM1-GM3",
                "Description": "Planar lipid bilayers were obtained and recorded using DOPC or mixtures of DOPC with GM3, GM1, or GM1 and GM3."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_000345.4:c.137G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "partial loss-of-function",
                    "Result Description": "The E46K mutation altered the channel properties of α-syn oligomers and generated nonstop activity in DOPC membranes. GM3 corrected these channelopathies, while GM1 did not."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "Experiments were performed at least five times under each condition."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Wild-type α-syn was used as a positive control."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "Control experiments were conducted with DOPC-only bilayers."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "Yes",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "No",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}
```

### 解释与补充说明：

1. **变异信息**：从文献中提取了与帕金森病相关的α-突触核蛋白（SNCA基因）中的E46K突变，其HGVS命名标准化为`NM_000345.4:c.137G>A`。

2. **疾病描述**：文献主要研究的是帕金森病（Parkinson's disease），对应的MONDO术语为`MONDO:0005072`。

3. **实验方法**：实验采用了平面脂质双层技术（Planar lipid bilayer technique），使用了合成的脂质膜（如DOPC、DOPC-GM3等）。该方法广泛用于研究帕金森病相关蛋白质的离子通道特性。

4. **读出描述**：E46K突变改变了α-突触核蛋白寡聚体的通道特性，并在DOPC膜中产生了持续活动。GM3能够纠正这些通道病变，而GM1则没有这种效果。

5. **生物和技术重复**：实验至少进行了五次，以确保结果的可靠性。此外，还设置了野生型α-突触核蛋白作为阳性对照，以及仅含DOPC的双层膜作为阴性对照。

6. **统计分析方法**：文献中未详细描述具体的统计分析方法，因此标注为“N.D.”（未提及）。

7. **正常和异常结果阈值**：文献中未明确给出这些阈值，因此基于专业知识进行了补充说明。

8. **批准的检测方法**：该实验方法是研究帕金森病的标准方法之一，因此标注为“是”。

通过这种方式，我们可以确保提取的信息准确且符合科学文献的标准。